A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

359

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

OTHER: Placebo for AZD8965
DRUG: AZD8965 low dose
DRUG: AZD8965 medium dose
DRUG: AZD8965 high dose

Sponsor

AstraZeneca